ReviewMicrobes and infection
Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system.
Review in Microbes and infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.Human vaccines & immunotherapeutics · 2026Article
- Cancer biotherapy: review and prospect.Clinical and experimental medicine · 2024Review
- Applications of Mass Spectrometry in the Characterization, Screening, Diagnosis, and Prognosis of COVID-19.Advances in experimental medicine and biology · 2024Article
- Recombinant Bacillus Calmette-Guérin Expressing SARS-CoV-2 Chimeric Protein Protects K18-hACE2 Mice against Viral Challenge.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Review
- Current clinical status of new COVID-19 vaccines and immunotherapy.Environmental science and pollution research international · 2022Review
- Vaccines platforms and COVID-19: what you need to know.Tropical diseases, travel medicine and vaccines · 2022Review
- Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach.Molecular biotechnology · 2022Article
- Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?Human vaccines & immunotherapeutics · 2021Review
- DNA vaccines for SARS-CoV-2: toward third-generation vaccination era.Expert review of vaccines · 2021Review
- An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.International immunopharmacology · 2021Review
- Review
- Perspectives on RNA Vaccine Candidates for COVID-19.Frontiers in molecular biosciences · 2021Review
- COVID-19: The Vaccine Race Continues.HCA healthcare journal of medicine · 2021Review
- COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.International immunopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
This article discusses standard and new disruptive strategies in the race to develop an anti-COVID-19 vaccine. We also included new bioinformatic data from our group mapping immunodominant epitopes and structural analysis of the spike protein. Another innovative approach reviewed here is the use of BCG vaccine as priming strategy and/or delivery system expressing SARS-CoV-2 antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.